Rapid ReviewThe prospects for immunotherapy in smoking cessation
Section snippets
Animal models of a nicotine vaccine
Animal studies provide strong proof of principle for a nicotine vaccine (panel 1).12, 13, 14 These have shown that antibodies can be induced by attaching nicotine to a suitable antigenic protein,12, 15, 16 these antibodies have high affinity for nicotine, and they do not cross-react with its major metabolite, cotinine, or the neurotransmitter acetylcholine.14, 15
Nicotine antibodies modify the pharmacokinetics and the pharmacological effects of nicotine in rats. Passive immunisation reduced the
Relapse prevention
Active vaccination against nicotine could prevent relapse to regular smoking in abstinent smokers by markedly attenuating the rewarding effects of nicotine for weeks to months. Ex-smokers could be given a series of vaccinations against nicotine as part of a behavioural treatment programme with the aim of reducing the chance of a “slip” leading to daily smoking.14
A nicotine vaccine has three potential advantages over NRT and bupropion in relapse prevention (Panel 2). First, it would not require
Challenges in delivering a nicotine vaccine
The marketing of a nicotine vaccine faces a problem that is less likely to be faced by vaccines against other pyschoactive drugs like cocaine and phencyclidine for which no effective pharmacotherapy exists. Competing smoking-cessation products such as NRT and bupropion may affect the degree of commercial interest in funding the clinical development and registration of a nicotine vaccine. Partnerships may be needed between public-health services and pharmaceutical companies to facilitate trials
Conclusions
Animal studies suggest that a nicotine vaccine is a biologically plausible immunotherapeutic intervention that could be used to successfully assist cigarette smokers to cease smoking. It has several potential advantages over existing pharmacotherapeutic aids to smoking cessation: it sequesters nicotine in the bloodstream, thereby preventing it from entering the brain, it may have fewer side-effects than drugs that act on the CNS, and it is likely to have better compliance than oral drugs.
References (24)
- et al.
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Lancet
(1997) - et al.
Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects of nicotine distribution to brain
Int J Immunopharmacol
(2000) - et al.
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats
Pharmacol Biochem Behav
(2000) Common aspects of the action of nicotine and other drugs of abuse
Drug Alcohol Depend
(1998)- et al.
Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome
Pharmacol Biochem Behaviour
(2001) - et al.
Longitudinal safety and immunogenicity of a therapeutic cocaine vaccine
Drug Alcohol Depend
(2000) Immunization for prevention and treatment of cocaine abuse: legal and ethical implications
Drug Alcohol Depend
(1997)- et al.
Neuronal systems underlying behaviours related to nicotine addiction: neuronal circuits and molecular genetics
J Neurosci
(2002) The health consequences of smoking: nicotine addiction
(1988)The nature of nicotine addiction